News

AmoyDx® Pan Lung Cancer PCR Panel submission forregulatory approval in Japan for the additional indication ofAmivantamab in combination with chemotherapy

TOKYO and XIAMEN, October 8, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co.,...

Oct 8

AmoyDx® Pan Lung Cancer PCR Panel Approved in Japan as The Primary Companion Diagnostic for IBTROZI® (Taletrectinib adipate)

TOKYO and XIAMEN, September 19, 2025 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co.,...

Sep 19

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnosticfor LORBRENA® (Lorlatinib)

TOKYO and XIAMEN, July 23, 2025 — Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd. (“PREMIA”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the AmoyDx® Pan Lung Cancer PCR Panel (the “AmoyDx® PLC Panel”) as a companion diagnostic (CDx) for indication of Amivantamab plus Lazertinib combination Therapy in Japan.

Aug 21

AmoyDx® Pan Lung Cancer PCR PanelApproved in Japan as a Companion Diagnostic indication of Amivantamab plus Lazertinib combination Therapy

Jul 23

AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Primary Companion Diagnostic for Taletrectinib

TOKYO and XIAMEN, March 27, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co., Ltd....

Mar 28

AmoyDx® Pan Lung Cancer PCR Panel application for approval in Japan as a Companion Diagnostic for LORBRENA ® Lorlatinib

TOKYO and XIAMEN, February 6th, 2025 -- Riken Genesis Co., Ltd., Amoy Diagnostics Co., Ltd. (“AmoyDx”), and Precision Medicine Asia Co.,...

Feb 6